Dicerna Pharmaceuticals, Inc.
DRNA
DRNA was delisted on the 27th of December, 2021.
54 hedge funds and large institutions have $313M invested in Dicerna Pharmaceuticals, Inc. in 2015 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 17 increasing their positions, 15 reducing their positions, and 7 closing their positions.
100% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 7
55% more capital invested
Capital invested by funds: $201M → $313M (+$112M)
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
15% more funds holding
Funds holding: 47 → 54 (+7)
13% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$21.8M |
| 2 |
O
OrbiMed
New York
|
+$4.39M |
| 3 |
ICM
ISZO Capital Management
New York
|
+$2.77M |
| 4 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
+$1.57M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$1.42M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
A
Abingworth
London,
United Kingdom
|
-$4.71M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$2.91M |
| 3 |
RI
RTW Investments
New York
|
-$2.81M |
| 4 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$2.57M |
| 5 |
OFM
Omega Fund Management
Boston,
Massachusetts
|
-$2.43M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Barclays
London,
United Kingdom
| $3K | -$2.07K | -92 | -45% |
|
52
BNP Paribas Financial Markets
Paris,
France
| $1.78K | +$1.66K | +74 | New |
|
53
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| $15 | – | – | – |
|
|
SFM
54
Sphera Funds Management
Tel Aviv,
Israel
| – | -$2.91M | -176,802 | Closed |
|
|
TCM
55
Tekla Capital Management
Boston,
Massachusetts
| – | -$2.57M | -156,250 | Closed |
|
|
SM
56
Sabby Management
Miami Beach,
Florida
| – | -$2.4K | -145,919 | Closed |
|
|
BCM
57
Bourgeon Capital Management
Darien,
Connecticut
| – | -$412K | -25,000 | Closed |
|
|
AL
58
Airain Ltd
St. Peter Port,
Guernsey
| – | -$173K | -10,500 | Closed |
|
|
BG
59
BlackRock Group
London,
United Kingdom
| – | -$54K | -3,277 | Closed |
|
60
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | +$157 | +7 | +350% |
|
DRNA Hedge Fund Activity: Q1 2015 in Review
54 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Dicerna Pharmaceuticals, Inc. (DRNA) for Q1 2015, worth a combined $313M — up 55% from $201M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new DRNA positions and 7 closed out — a net gain of 7 holders — while 17 added to existing stakes and 15 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $21.8M. The largest seller was Abingworth, cutting an estimated $4.71M.
- 54 institutional investors held Dicerna Pharmaceuticals, Inc. (DRNA) as of Q1 2015, up from 47 in Q4 2014.
- Funds reported $313M of Dicerna Pharmaceuticals, Inc. stock for Q1 2015, up 55% quarter-over-quarter.
- 14 funds opened new Dicerna Pharmaceuticals, Inc. positions in Q1 2015 and 7 closed out, a net change of +7 holders.
- The largest Dicerna Pharmaceuticals, Inc. buyer in Q1 2015 was Wellington Management Group, an estimated $21.8M added.
- The largest Dicerna Pharmaceuticals, Inc. seller in Q1 2015 was Abingworth, an estimated $4.71M sold.
Based on aggregated 13F filings for Q1 2015.